Sexual dysfunction following prostate cancer treatment
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
INTRODUCTION AND OBJECTIVE:Symptoms of overactive bladder (OAB) may persist in men being treated for benign prostatic hyperplasia (BPH). Vibegron is a selective β3 agonist being…
The AUA invites the global urologic community to the 119th AUA Annual Meeting in the dynamic city of San Antonio, TX!
INTRODUCTION AND OBJECTIVE:The use of AI-powered chatbots is increasingly finding application in healthcare. AI-based chatbots can act as automated conversational agents, capable of promoting health…
Friday, May 3, 2024 3:15 PM to 3:45 PM · 30 min. (US/Central)
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…
Topic: Spatial Biology in Benign and Malignant Urologic Disease Symposium Goal: Benign and malignant prostate diseases display high cellular heterogeneity. While single cell assays provide…
A phase 3 trial demonstrates a high rate of complete response with cretostimogene, an investigational immunotherapy administered intravesically.
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…
AUA 2024 advanced prostate cancer, molecular imaging (mi) node positive disease (miN1) undergoing radical prostatectomy, extended pelvic lymph node dissection (ePLND).
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…